| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| B Ahrén, J E Fole. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. International journal of clinical practice. Supplement. issue 159. 2008-07-31. PMID:18269436. |
mechanistic studies of vildagliptin performed to characterise the effects of dpp-4 inhibition on pancreatic islet function and glucose metabolism have found that vildagliptin produces dose-dependent reductions in dpp-4; these result in persistent levels of active glp-1 and gip in the circulation leading to improved beta-cell sensitivity to glucose and glucose-dependent insulin secretion, and improved alpha-cell sensitivity to glucose and reduction in inappropriate glucagon secretion. |
2008-07-31 |
2023-08-12 |
human |
| R Keith Campbell, John R Whit. More choices than ever before: emerging therapies for type 2 diabetes. The Diabetes educator. vol 34. issue 3. 2008-07-29. PMID:18535325. |
glycemic control, defined by the american diabetes association (ada) as hba(1c) <7.0%, is often difficult to achieve despite current treatments, including oral antidiabetes agents, such as biguanides (metformin), sulfonylureas, thiazolidinediones, dipeptidyl peptidase-iv (dpp-iv) inhibitors, meglitinides, and alpha-glucosidase inhibitors, as well as injectable agents, such as glucagon-like peptide-1 (glp-1) analogues and insulin. |
2008-07-29 |
2023-08-12 |
Not clear |
| P J Larsen, E M Wulff, C F Gotfredsen, C L Brand, J Sturis, N Vrang, L B Knudsen, K Lykkegaar. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. Diabetes, obesity & metabolism. vol 10. issue 4. 2008-07-28. PMID:18333889. |
combination of the insulin sensitizer, pioglitazone, and the long-acting glp-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic zdf rats. |
2008-07-28 |
2023-08-12 |
human |
| S Efendic, M Alvarsson, K Brismar, H Wagne. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs. Acta physiologica (Oxford, England). vol 192. issue 1. 2008-07-11. PMID:18171434. |
when patients treated with metformin, sulfonylurea (su), tiazolidinediones or a combination of these drugs fail, the glp-1 mimectics may be preferred to insulin treatment. |
2008-07-11 |
2023-08-12 |
Not clear |
| S Efendic, M Alvarsson, K Brismar, H Wagne. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs. Acta physiologica (Oxford, England). vol 192. issue 1. 2008-07-11. PMID:18171434. |
patients not responding to glp-1 mimetics or experiencing significant side effects will be treated with insulin. |
2008-07-11 |
2023-08-12 |
Not clear |
| Bo Ahré. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vascular health and risk management. vol 4. issue 2. 2008-07-10. PMID:18561513. |
both fasting and prandial glucose are reduced by dpp-4 inhibition in combination with metformin in association with improvement of insulin secretion and insulin resistance and increase in concentrations of active glp-1. |
2008-07-10 |
2023-08-12 |
Not clear |
| Fàtima Sabench Pereferrer, Mercè Hernàndez Gonzàlez, Albert Feliu Rovira, Santiago Blanco Blasco, Antonio Morandeira Rivas, Daniel del Castillo Déjardi. Influence of sleeve gastrectomy on several experimental models of obesity: metabolic and hormonal implications. Obesity surgery. vol 18. issue 1. 2008-06-24. PMID:18066699. |
the aim of this experimental study was to analyze the effect of sleeve gastrectomy (removing fundus) on the volume of intake in four experimental models and determine how this relates to changes in weight, plasmatic levels of glycemia, ghrelin, glp-1, and insulin. |
2008-06-24 |
2023-08-12 |
Not clear |
| Steffen Runge, Henning Thøgersen, Kjeld Madsen, Jesper Lau, Rainer Rudolp. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. The Journal of biological chemistry. vol 283. issue 17. 2008-06-19. PMID:18287102. |
glp-1 is involved in glucose homeostasis, and activation of glp-1r in the plasma membrane of pancreatic beta-cells potentiates glucose-dependent insulin secretion. |
2008-06-19 |
2023-08-12 |
human |
| Sheila A Doggrel. Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide. Reviews on recent clinical trials. vol 2. issue 1. 2008-06-17. PMID:18473991. |
one of the actions of glp-1 is to stimulate insulin secretion. |
2008-06-17 |
2023-08-12 |
human |
| Sheila A Doggrel. Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide. Reviews on recent clinical trials. vol 2. issue 1. 2008-06-17. PMID:18473991. |
in subjects with type 2 diabetes, intravenous or subcutaneous glp-1 stimulated insulin production and decreased blood glucose levels. |
2008-06-17 |
2023-08-12 |
human |
| Luc F Van Gaal, Stephen W Gutkin, Michael A Nauc. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? European journal of endocrinology. vol 158. issue 6. 2008-06-16. PMID:18322302. |
glucagon-like peptide 1 (glp-1) is an incretin hormone released by the gut in response to meal intake that helps to maintain glucose homeostasis through coordinated effects on islet alpha- and beta-cells, inhibiting glucagon output, and stimulating insulin secretion in a glucose-dependent manner. |
2008-06-16 |
2023-08-12 |
Not clear |
| Fenghua Yi, Jane Sun, Gareth E Lim, I George Fantus, Patricia L Brubaker, Tianru Ji. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. vol 149. issue 5. 2008-06-10. PMID:18258680. |
we show here that 100 nm insulin stimulated glu expression and enhanced glp-1 content in the intestinal glutag l cell line as well as in primary fetal rat intestinal cell cultures. |
2008-06-10 |
2023-08-12 |
mouse |
| Noriyuki Sonoda, Takeshi Imamura, Takeshi Yoshizaki, Jennie L Babendure, Juu-Chin Lu, Jerrold M Olefsk. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 18. 2008-05-28. PMID:18445652. |
glucagon-like peptide-1 (glp-1) is a polypeptide hormone secreted from enteroendocrine l cells and potentiates glucose-dependent insulin secretion in pancreatic beta cells. |
2008-05-28 |
2023-08-12 |
Not clear |
| Noriyuki Sonoda, Takeshi Imamura, Takeshi Yoshizaki, Jennie L Babendure, Juu-Chin Lu, Jerrold M Olefsk. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 18. 2008-05-28. PMID:18445652. |
here we identify a mechanism for glp-1 action, showing that the scaffold protein beta-arrestin-1 mediates the effects of glp-1 to stimulate camp production and insulin secretion in beta cells. |
2008-05-28 |
2023-08-12 |
Not clear |
| Noriyuki Sonoda, Takeshi Imamura, Takeshi Yoshizaki, Jennie L Babendure, Juu-Chin Lu, Jerrold M Olefsk. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 18. 2008-05-28. PMID:18445652. |
beta-arrestin-1 knockdown broadly attenuated glp-1 signaling, causing decreased erk and creb activation and irs-2 expression as well as reduced camp levels and impaired insulin secretion. |
2008-05-28 |
2023-08-12 |
Not clear |
| Noriyuki Sonoda, Takeshi Imamura, Takeshi Yoshizaki, Jennie L Babendure, Juu-Chin Lu, Jerrold M Olefsk. Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 18. 2008-05-28. PMID:18445652. |
taken together, these studies indicate that beta-arrestin-1 plays a role in glp-1 signaling leading to insulin secretion, defining a previously undescribed mechanism for glp-1 action. |
2008-05-28 |
2023-08-12 |
Not clear |
| Paul Kuo, Reawika Chaikomin, Amelia Pilichiewicz, Deirdre O'Donovan, Judith M Wishart, James H Meyer, Karen L Jones, Christine Feinle-Bisset, Michael Horowitz, Christopher K Rayne. Transient, early release of glucagon-like peptide-1 during low rates of intraduodenal glucose delivery. Regulatory peptides. vol 146. issue 1-3. 2008-05-15. PMID:17964673. |
the "incretin" hormones, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), account for some 60% of the stimulation of insulin by oral glucose, but the determinants of their secretion from the small intestine are poorly understood. |
2008-05-15 |
2023-08-12 |
Not clear |
| D Tews, U Werner, J Ecke. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 40. issue 3. 2008-05-13. PMID:18348079. |
the aim of this study was to test if the anti-apoptotic activity of glp-1 agonists and insulin analogues is mediated by different pathways and if combined treatment may provide augmented protection against beta-cell death. |
2008-05-13 |
2023-08-12 |
Not clear |
| D Tews, U Werner, J Ecke. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 40. issue 3. 2008-05-13. PMID:18348079. |
we show here that the anti-apoptotic activity of glp-1 and its receptor agonists ave0010 and exendin-4 is enhanced by addition of insulin analogues and that the anti-apoptotic action of glp-1 mimetics is mostly unrelated to akt2 signaling. |
2008-05-13 |
2023-08-12 |
Not clear |
| D Tews, U Werner, J Ecke. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 40. issue 3. 2008-05-13. PMID:18348079. |
it is suggested that combination of glp-1 receptor agonists and insulin analogues, specifically insulin glargine, may represent a new therapeutic option for preservation of beta-cell mass in type 2 diabetic patients. |
2008-05-13 |
2023-08-12 |
Not clear |